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The homophilic potential emerges as an important biological principle to boost the
potency of immunoglobulins. Since homophilic antibodies in human and mouse sera
exist prior environmental exposure, they are part of the natural antibody repertoire.
Nevertheless, hemophilic properties are also identified in induced antibody repertoire.
The use of homophilicity of antibodies in the adaptive immunity signifies an archetypic
antibody structure. The unique feature of homophilicity in the antibody repertoire also
highlights an important mechanism to boost the antibody potency to protect against
infection and atherosclerosis as well to treat cancer patients.
Keywords: natural antibodies, homophilic, immunoglobulins, idiotype, induced antibodies, T15, 1F7

NATURAL ANTIBODIES – THE VIRGIN IMMUNE RESPONSE
Natural antibodies are immunoglobulins in sera of mammalians that are neither immunologically
challenged nor responding. For example, natural antibodies are in sera of neonatal or germ-free
mice. Natural antibodies are of IgM, IgG, and IgA isotypes and play an important role in the immune
homeostasis and protection against pathogens (1–6). B1 cells in mice produce natural antibodies (7, 8). In human, CD20+CD27+CD43+ memory B cells were recently identified as murine B1
counterpart (9). Natural antibodies are the important components of the therapeutic intravenous
immunoglobulin (IVIG) (10–12) that is widely used in the therapy of autoimmune and inflammatory diseases (13–17). These functions of natural antibodies also indicate diverse roles played by
B cells in the immune homeostasis (18–22).

THE IDIOTYPIC INTERACTIONS
Oudin and Jerne are the founders of the idiotype concept (23, 24). They “discovered” that one antibody could recognize another antibody as an individual and unique member of the immune system.
The uniqueness of an antibody lies in the variable region of heavy and light chains and has been
named idiotype. The idiotype antibody individuality is separated from the antigen-binding site, also
determined by unique sequence variability. However, both regions are linked by a unique variability
and have a functional relation. Identifying an antigen-binding site also reveals the linked idiotype
and vice versa, an idiotope reveals the associated antigen specificity. However, there are important
exceptions to this linkage rule: the so-called common idiotopes (IdX) are expressed on antibodies
with different antigen specificities (25). Furthermore, antigen-binding site and idiotype site can be
identical or overlapping.
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Studies on the functional interactions of anti-idiotype
binding to antibodies have established a classification in the
idiotype field. Jerne termed anti-idiotypes that do not interfere with the antigen-binding site as Ab2α and anti-idiotypes
that block the antigen binding as Ab2β (26). Ab2 was further
differentiated by adding the term Ab2γ to describe Ab2 that
only partially inhibits antigen binding (27, 28). The Ab2β has
another unique functional feature. It mimics the antigen by its
perfect fit into another antigen-binding site. Ab2β has been
used as an antigen to induce a specific immune response (28).
Another shared idiotype has been discovered in HIV-infected
primates (29). This anti-idiotype antibody has been termed as
Ab2δ (30).
In mice, “prime” antibodies lack the dominant expression of
certain shared idiotype, such as the so-called T15 idiotype, that
develops weeks after birth without environmental challenge (31,
32). Therefore, the T15 dominance can be considered a part of
the natural antibody repertoire. The T15 idiotype is also present
in primates, including man (33). Perhaps a review of the idiotypic circuits is helpful for the understanding of the biological
and immunological properties of the T15 archetypic idiotype.
A hallmark of the T15 antibody family is their ability to self
bind for producing homophilic complexes (34–36). The domain
responsible for antibody self-binding (homophilicity) has been
described as a region in VH of T15, extending from CDR2 to
Fr3 (35, 37). Because of their preimmune presence in normal
sera, homophilic antibodies are segment of the natural antibody
repertoire (33, 37).

Indeed, human natural antibodies with specificity for PC
protect against atherosclerotic plaque formation by binding
to oxidized LDL and inhibit macrophage activation (43, 47).
Immunizing atherosclerotic mice with PC antigen reduces
plaque formation (44). Silverman and colleagues showed that SLE
patients with low natural antibodies develop more serious disease
(48). Emerging evidence suggested that natural antibodies could
control transplant rejection (49).
Another “natural” antibody in normal human sera has been
described with specificity for HLA (50). This anti-HLA is not
detectable in sera but is revealed after IgG purification. The
homophilic T15 peptide from the complementarity-determining
region/framework masked the HLA recognition of non-purified
IgG. Since the T15 homophilic peptide dissociate the homophilic
Ig complex, thereby reducing the polyvalency and binding
potency, one can conclude that in sera, auto-anti-HLA antibodies
are bound to corresponding HLA and are not detected. It follows
that natural auto-anti-HLA antibodies are homophilic. Thus, the
homophilic property of antibodies plays a role in the functional
regulation of antibodies either by masking them or by exposing
them under appropriate conditions.
A homophilic state of the Ig B-cell receptor (BCR) has been
described in chronic lymphocytic leukemia (51, 52). Peptides
from the VH Ig BCR bind to the BCR providing the basis for selfrecognition of the BCR. Recently, we used the T15 homophilic
peptide to inhibit proliferation of murine human B-cell lines (46).

THE UNIQUE BIOPHYSICAL PROPERTIES
OF HOMOPHILIC ANTIBODIES

THE BIOLOGY AND IMMUNOREGULATORY
FUNCTIONS OF HOMOPHILIC ANTIBODIES

Working with homophilic-converted Trastuzumab (Herceptin),
we discovered that the dose–response in inducing apoptosis in a
Her2/neu-expressing human cell line was not linear but was bell
shaped (53). The highest concentration tested did not induce the
highest amount of apoptosis, but a lower concentration produced
the most apoptosis. Similar non-linear dose effects were observed
in fluorescence staining of tumor cells. This paradoxical dose
effect was also observed in xenograft experiment (54).
This non-linear dose affecting the potency of homophilic
Herceptin could be due to the inherent mechanic of self-binding
that was observed in 1986 (37, 55). Here, self-binding of the T15
antibody decreases as the concentration of homophilic antibody
increases, producing a bell-shaped pattern. This indicates that the
equilibrium of self-bound antibody and free antibody is controlled
by the concentration of homophilic antibody. Thus, the lattice of
build up of homophilic antibodies at the tumor target cell would
decrease at a higher concentration, thereby reducing apoptosis.
This paradoxical effect has been observed with homophilic antiHer2/neu (Herceptin) (54). In this study, we showed that the
viscosity of homophilic antibodies increases with temperature
and decreases at lower temperature, an effect not observed with
the most other proteins or organic compounds. Furthermore,
the binding to antigen by a homophilic antibody is also higher at
physiological temperature than by the non-homophilic parental
antibody. Lastly, the binding of homophilic Herceptin to tumor
cells is concentration dependent, whereby a lower concentration

The homophilic domain in antibodies was identified, and peptides that can confer the homophilic effect to other antibodies
were made (38). Further studies showed that the homophilic
domain can be expressed independently from the specificity of
the antigen-binding site (39). This suggested that any antibody
could be made homophilic by attaching the homophilic domain.
In early experiments, a chemical affinity conjugation method was
introduced to make the homophilic Ig (40); later, recombinant
techniques were used to produce a homophilic antibody fusion
protein.
Human and mouse sera contain antibodies that express the
homophilic domain (33), confirming that homophilic antibodies
are part of the so-called natural antibodies (41). Homophilic antibodies with specificity for phosphorylcholine (PC) are superior
in protecting against Streptococcus pneumoniae infection (42).
Homophilic anti-PC antibodies are also highly effective to reduce
atherosclerotic plaque formation (43, 44) and perhaps have other
housekeeping functions. Antigenicity of the homophilic domain
was tested in mice, rabbits, and non-human primates by injecting the homophilic domain peptide and treating macaques with
a homophilic anti-CD20 antibody (45). No antibodies could be
detected against the homophilic domain. This finding suggests
that homophilic antibodies could be used as therapeutic drugs to
treat human diseases without allergic side effects (46).
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targets better than a higher concentration. The unique biophysical properties of homophilic antibodies represent another aspect
in the natural antibody repertoire.

of homophilic domains is found different (51, 52). Thus, certain
homophilic antibodies are not part of the so-called natural antibodies but are induced by antigenic stimulation.
The homophilic antibody enhancement and therapeutic
potential have been already demonstrated (38, 46). The native
dominant expression of 1F7 idiotype on anti-HIV-1 antibodies
may lead to a novel vaccine concept (65). There is one important
difference between the T15 and the 1F7 system: T15 antibodies are present in preimmune serum without external antigen
exposure; 1F7 antibodies recognizing anti-HIV and anti-HBC
antibodies are induced after infection and are not natural antibodies. Nemazee et al. recently promoted the idea of targeting
germline antibodies for inducing a maturation sequence, leading to broadly neutralizing Abs against HIV-1 (66). The use of
a germline targeting immunogen is different from the concept
of stimulating B-cells with idiotype expressing receptors. Prior
to triggering, these B-cells do not produce detectable antibodies
and do not contribute to the natural antibody repertoire (57).
Using the 1F7 antibody as vaccine would not require additional
immunogen(s) to trigger the antibody maturations process, since
the 1F7 idiotype is expressed by potent broadly neutralizing Abs
(Parsons, unpublished). HIV-1 infection is expected to stimulate
the expanded clones of 1F7 expressing B-cells to produce broadly
neutralizing Abs (57).

HOMOPHILICITY IN SHARED IDIOTYPES
We believe that we are only at the beginning to discover networks
of shared idiotypes. By using polyclonal anti-idiotype antibodies,
Urbain and colleagues have observed shared idiotypes expressed
on antibodies with different antigen specificity in rabbits and mice
(26, 56). The monoclonal 1F7 anti-idiotype recognizes antibodies
against viral antigens and is first described in humans (29, 57, 58).
The T15 and 1F7 idiotypic networks harbor important biological
and medical properties: dominant T15 antibodies protect against
pneumococcal infection (59) and perform a housekeeping
function to reduce atherosclerotic plaque formation (43); the
1F7 idiotope is expressed on antibodies against HIV-1 (57, 60)
and hepatitis C (61, 62) (see also contribution by Muller et al.).
Furthermore, 1F7-positive human anti-HIV-1 antibodies carry
the homophilic domain (Veljkovic and Kohler, unpublished).
These studies on homophilic antibodies show that homophilicity
is utilized in the innate immunity (natural antibodies) and by the
adaptive immune response.

HOMOPHILICITY AS A GENERAL
CONCEPT IN SYSTEM BIOLOGY OF
NATURAL ANTIBODIES

SUMMARY
The discussion of the unique feature of homophilicity as a part of
the natural and induced antibody repertoires (65) highlights an
important mechanism to boost the antibody potency to protect
against infection and atherosclerosis (44) as well to treat cancer
patients (46). The concept of homophilicity is introduced here
to describe the unique coexistence and synergism of acquired
immunity with innate immunity. The homophilicity of antibodies
in the natural and acquired repertoires emerges as an archetypic
principle in the immune system.

The data on homophilic natural antibodies point to a general
strategy of enhancing potency not only of antibodies but also
other biological systems (63). This finding can be viewed as a
paradigm in System Biology in the T15 and 1F7 idiotypic networks. Both systems utilize the antibody homophilicity. Both
systems also use this property to achieve a high level of antibody
potency. Antibodies with T15 expression in normal sera are
close to germline encoding: (i) the T15 dominance develops
late in ontogeny (31), (ii) the homophilic domain contains H2
mutations, (iii) analysis of the neonatal repertoire by Coutinho
(64) shows only evidence for extensive idiotypic network and for
homophilic binding, and (iv) homophilic antibodies have been
detected after stimulation (38, 46). Furthermore, in support of
the adaptive creation of the homophilic domain, the sequence
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